Yes, Teclistamab, marketed under the brand name Tecvayli, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma in adults who have tried at least four previous lines of therapy. These therapies must include a proteasome inhibitor, an immunomodulatory... read more

Yes, Teclistamab, marketed under the brand name Tecvayli, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma in adults who have tried at least four previous lines of therapy. These therapies must include a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Teclistamab is a bispecific T-cell engager that targets the BCMA protein on myeloma cells and the CD3 protein on T cells, aiming to activate T cells to kill myeloma cells. It's administered as a subcutaneous injection. Clinical studies have shown that nearly two-thirds of people with relapsed or refractory multiple myeloma responded to treatment with Teclistamab, and 40 percent achieved complete remission, meaning they had no remaining signs of myeloma after using the drug.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment | MyMyelomaTeam

Tecvayli (Teclistamab-cqyv) for Myeloma | MyMyelomaTeam